Rona Therapeutics' metabolic assets
have demonstrated a differentiated profile to address
unmet medical needs in cardiovascular diseases, obesity and MASH
PLATFORM
GAIA
Liver delivery platform
Long dosing intervals to improve patient compliance
Convenient subcutaneous injection
Novel GalNAc and chemical modifications to improve potency and safety
APOLLO
Extraheptic delivery platform
Small molecule conjugation for efficient receptor mediated uptake throughout the CNS
Intrathecal local delivery to minimize side effects associated with systemic exposure
Q6M or longer dosing schedule with proof-of-concept in non-human primates
Bi-Valent/Multi-Valent
Plug-and-Play Scalable Platform
Ideal for complex diseases caused by multiple factors, such as cardiovascular diseases and obesity
Potential to treat two or more diseases by impacting two targets
Synergistic efficacy without added side effects
Streamline development and better marketing potential than fixed dose combination
PIPELINE
GAlA Platform
RN0361
Hypertriglyceridemia ApoC3RN3161
Obesity INHBERN5681
ASCVD Lp(a)-PCSK9NEWS
CONTACT US
China
Email:
BD@ronatherapeutics.com / HR@ronatherapeutics.com
Address:
Tower 3, JNB Life Science Park, No.795,
Kangwei Road, Pudong New Area, Shanghai, China
Australia
Email:
BD@ronatherapeutics.com
Address:
Se 2 202-220 FERNTREE GULLY RD
CLAYTON VIC
3168
United States
Email:
BD@ronatherapeutics.com
Address:
State of Delaware
Jinyu Huang, Ph.D.
Chief Executive Officer, Founder
Stella Shi is founder, Chief Executive Officer and chairs the board of Rona Therapeutics since company inception in 2021 bringing ~15 years of biopharmaceutical industry and venture capital experience. Prior to founding Rona Therapeutics, Stella was managing director in Lilly Asia Ventures (LAV) from 2015 with proven track records with various venture creation ...